Tecentriq’s revenue trends
In 3Q17, Roche Holding’s (RHHBY) Tecentriq generated revenues of 118 million Swiss francs, which reflected ~104% growth on a year-over-year (or YoY) basis and a 5% fall on a quarter-over-quarter (or QoQ) basis. In 3Q17 in the US and European markets, Tecentriq generated revenues of 112 million Swiss francs and 2 million Swiss francs, respectively, which reflected ~99% and ~130% growth, respectively, YoY.
In September 2017, the European Commission (or EC) approved marketing authorization for Tecentriq as a monotherapy for patients with locally advanced or metastatic NSCLC (non-small cell lung cancer) who previously underwent chemotherapy, irrespective of PD-L1 (programmed death-ligand 1) status.
In September 2017, the EC also provided marketing authorization for Tecentriq as a monotherapy for patients with locally advanced or metastatic urothelial carcinoma (or mUC) who previously underwent a platinum-containing chemotherapy or are not candidates for cisplatin chemotherapy, irrespective of PS-L1 status. The two EC approvals are expected to boost sales growth for Tecentriq.
Alecensa’s revenue trends
In 3Q17, Alecensa generated revenues of 96 million Swiss francs compared to 49 million Swiss francs in 3Q16. In 3Q17, Alecensa witnessed a 20% growth on a QoQ basis. In 3Q17, in the US, European, and Japanese markets, Alecensa generated revenues of 45 million Swiss francs, 9 million Swiss francs, and 38 million Swiss francs, respectively. Alecensa (alectinib) is used for the treatment of individuals with ALK-positive (anaplastic lymphoma kinase–positive) metastatic NSCLC whose disease progression continued or who are not tolerant to crizotinib.
In October 2017, the EC’s Committee for Medicinal Products for Human Use (or CHMP) recommended a positive opinion for the approval of Roche’s Alecensa as a monotherapy for first-line treatment of individuals with ALK-positive advanced NSCLC. CHMP has also recommended changing the current conditional marketing approval for Alecensa for crizotinib’s failure to complete marketing approval.
Roche’s Alecensa competes with Novartis’s (NVS) Zykadia and Eli Lilly’s (LLY) Cyramza. Some other important drugs for NSCLC include Bristol-Myers Squibb’s (BMY) Opdivo, Novartis’s Tafinlar and Mekinist, and AstraZeneca’s Iressa.
Revenue growth of Roche’s Tecentriq and Alecensa could boost revenue growth for the Vanguard FTSE All-World ex-US ETF (VEU). Roche makes up ~0.71% of VEU’s total portfolio holdings.